Role of Mentosoothe Compound in the Management of Attention Deficit Hyperactivity Disorder

Clinical Study to evaluate the efficacy of Mentosoothe compound in the management of Attention-Deficit/Hyperactivity Disorder

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055683

Enrollment

Registered

2023-07-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F902- Attention-deficit hyperactivity disorder, combined type

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1 Children of either sex in between age group of 5 to 10 years. 2 Known case of ADHD. 3 Children with average/normal IQ 4 Subjects satisfying DSM-5 criteria of diagnosis

Exclusion criteria

Exclusion criteria: • Children with any critical mental disease. • Children with known gross physical disability. • Children with any known genetic disorder and congenital disorder. • Children with any associated long term or fatal disease. • Children with known systemic disorder like Diabetes Mellitus, Nephrotic syndrome etc.

Design outcomes

Primary

Measure	Time frame
•Change in the scoring/grading of symptom of ADHD on NICHQ Vanderbilt Assessment scale.Timepoint: 3 months	—

Secondary

Measure	Time frame
• Improve in the quality of life by improvement in cognition & concentration with safe and effective treatmentTimepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Rakesh kumar nagar

National Institute of Ayurveda , Jaipur

drrknagar@gmail.com9414062099

Outcome results